ec2
 

John
Newman Oppenheimer

Director of the Specialty Pharmaceuticals Research Team of Oppenheimer and Co.

New York, New York

Oppenheimer and Co. Executive John Newman Oppenheimer possesses more than five years of experience in biotechnology, pharmaceutical research, and analysis. Currently, John Newman Oppenheimer leads the Specialty Pharmaceuticals Research team of Oppenheimer and Co. Based in New York, Oppenheimer and Co. provides investment services and guidance to high net-worth clients.

John Newman Oppenheimer became Director of the Specialty Pharmaceuticals Research team after serving as a Senior Specialty Pharmaceuticals Analyst. In this role, John Newman Oppenheimer maintains coverage of 23 companies, having accumulated the first 12 within six months of joining Oppenheimer and Co. John Newman Oppenheimer also publishes research reports and markets with corporate clients.

Prior to joining Oppenheimer and Co., John Newman Oppenheimer supported the Biotechnology Research team at Merrill Lynch. As an Associate Analyst, John Newman Oppenheimer wrote company reports, maintained models, and acted as a liaison between Merrill Lynch and clients on covered companies. John Newman Oppenheimer holds a Bachelor of Science degree in Chemistry from Loyola University in Chicago, Illinois.

Upon completing his undergraduate education, John Newman Oppenheimer entered the Howard Hughes Medical Institute at the University of Maryland, where he obtained a Ph.D in Chemistry. During his time with the program, John Newman Oppenheimer published three scientific papers. In addition to his education and professional experience, John Newman Oppenheimer garnered a post-doctorate fellowship at the University of Wisconsin-Madison, studying biochemistry and business.

In his free time, John Newman Oppenheimer enjoys staying physically active as a member of the New York Road Runners. John Newman Oppenheimer also regularly donates to charities like the March of Dimes, the Leukemia and Lymphoma Society, and the American Cancer Society.


John Newman Oppenheimer's Schools

John Newman Oppenheimer's Companies

  		•  Oppenheimer and Co. 2008
    Director
    John Newman joined Oppenheimer in June 2008 as the Senior Specialty Pharmaceuticals Analyst. Prior to joining Oppenheimer, he was an associate analyst at Merrill Lynch on a top-ranked biotechnology team concentrating on oncology-focused names.

John Newman Oppenheimer's Publications

  • The Labrador Retriever, John Newman Oppenheimer
    December, 2010
    By: John Newman Oppenheimer

    Originating in Newfoundland, the Labrador Retriever is a dog with a diverse history and fascinating characteristics that make it effective in a variety of ways. Evolved from the St. John Dog, the Labrador has webbed paws, which lend it great efficiency in swimming. Its webbed paws are indicative of its original purpose: retrieving fishing nets from water. Known worldwide as the most popular type of dog, Labradors are loving animals who enjoy being close to and showing affection for their owners. Besides their status as pets, Labs have a number of qualities that make them useful in a large number of pursuits. For many decades, Labradors have accompanied hunters on expeditions. Specifically, retrievers fetch downed fowl on a hunter’s behalf. The Labrador’s refined sense of smell is often able to guide him quickly to his target. However, if a Labrador Retriever is unsure of a bird’s position, the hunter can guide the dog using different types of hand signals and whistles. The intelligence of Labradors makes them efficient assistance dogs. The Labrador’s intelligence, combined with a strong work ethic and a calm demeanor, have garnered the dogs much recognition in this capacity. Some Labradors have been known to go so far as helping victims by fetching blankets, covering the injured party, and then dashing off to the nearest human and barking for help. Labradors are also suitable as detector dogs for police and other official organizations charged with searching out specific targets. The Labrador’s excellent sense of smell is instrumental toward this end. For pet owners or officials in need of a dog that exhibits intelligence, athleticism, and the ability to undertake tasks before a human can name them, Labradors come highly recommended.

  • An Overview of Merrill Lynch, By John Newman
    October, 2011
    John Newman presently serves Citadel Securities, LLC, an equity and options market-making firm based in Chicago, in the capacity of Director of Biotechnology and Specialty Pharmaceuticals. Mr. Newman gained experience in this sector while working for Merrill Lynch from 2005 to 2008. Serving as an Associate Analyst on a biotechnology research team at Merrill Lynch, Mr. Newman wrote company reports and maintained models for one of the world’s premier wealth management, securities, corporate finance, and investment banking firms.

    Merrill Lynch collaborates with over 60,000 global partners in 40 countries, combining its influential product resources, technology, and capital with local market knowledge all over the world. The Washington Post described Merrill Lynch in a 2008 news article as one of the world’s “most celebrated investment banking firms.”

    Bank of America Corporation acquired Merrill Lynch in 2008, as the end result of a merger that united the company with one of the largest consumer banks in the nation. In addition to its banking resources, Bank of America provides a comprehensive range of investment, asset management, risk management, and other products and services for individuals, businesses, and large corporations.

    Maintaining partnerships with more than 59 million retail banking offices, Bank of America helps support more than 4 million small business owners through its product and service innovations. In the years following its acquisition of Merrill Lynch, Bank of America attained a status as the largest brokerage in the world, with more than 15,000 financial advisors helping manage $2.2 trillion in assets.